Nanobiotix S.A. (NBTX) Key Metrics
NBTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosNBTX returns How much profit the business earns on the capital it uses.
NBTX financial health Debt, liquidity and how easily interest is covered.
NBTX efficiency & capital use Working capital cycle and where the cash goes.
NBTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NBTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NBTX key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −96.7% | −98.0% | — | −104.3% | −85.3% | −132.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | −736.1% | — | — | — | −661.9% |
| Return on assets (ROA) | −35.5% | −84.5% | −51.7% | −70.6% | −39.9% | −35.3% | −99.4% | −58.5% | −59.5% | −77.0% |
| Return on tangible assets | −35.4% | −101.1% | −42.3% | −95.4% | −46.2% | −25.1% | −90.9% | −65.8% | −45.6% | −72.0% |
| Free cash flow margin | −114.6% | — | −35.4% | −778.8% | — | — | — | −758.9% | −598.8% | −344.6% |
| Financial health | ||||||||||
| Total debt | €95.3M | €50.9M | €50.6M | €53.2M | €46.0M | €49.0M | €44.5M | €20.5M | €4.7M | €5.7M |
| Cash & short-term investments | €52.8M | €49.7M | €75.3M | €41.4M | €84.2M | €119.2M | €35.1M | €36.2M | €47.2M | €21.1M |
| Net debt | €42.6M | €1.2M | −€24.7M | €11.8M | −€38.1M | −€70.2M | €9.4M | −€15.7M | −€42.5M | −€15.4M |
| Debt / equity | — | — | — | — | 1.72 | 0.70 | — | 1.44 | 0.11 | 0.33 |
| Debt / assets | 1.41 | 0.76 | 0.54 | 0.89 | 0.45 | 0.37 | 0.79 | 0.44 | 0.08 | 0.19 |
| Current ratio | 1.09 | 1.04 | 1.75 | 1.38 | 2.53 | 6.58 | 3.22 | 3.68 | 5.68 | 3.26 |
| Quick ratio | 1.09 | 1.04 | 1.75 | 1.30 | 2.61 | 8.70 | 3.03 | 3.58 | 6.20 | 3.87 |
| Interest coverage | -1.0 | -8.5 | -3.4 | -8.0 | -75.2 | -109.4 | -9.8 | -35.5 | -233.2 | -213.8 |
| Working capital | €5.2M | €2.5M | €37.5M | €14.4M | €56.2M | €106.2M | €31.8M | €31.1M | €43.8M | €18.6M |
| Invested capital | −€41.9M | −€64.5M | −€26.6M | −€15.3M | −€11.4M | €296,000 | €7.5M | −€1.4M | €1.4M | €2.0M |
| Tangible asset value | −€84.5M | −€65.7M | −€1.9M | −€27.0M | €26.8M | €70.4M | −€2.1M | €14.1M | €43.8M | €17.4M |
| Net current asset value | −€89.5M | −€71.7M | −€8.4M | −€34.5M | €18.1M | €61.7M | −€12.0M | €10.7M | €39.6M | €13.9M |
| Capital allocation | ||||||||||
| Dividends paid | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | — | — |
| Capex / revenue | 1.8% | — | 0.9% | 1.9% | 8.6% | 4.1% | 42.9% | 12.0% | 36.0% | 7.4% |
| Capex / depreciation | 0.37 | 0.52 | 0.22 | 0.06 | 0.15 | 0.05 | 0.62 | 0.67 | 2.74 | 0.83 |
| Stock-based compensation / revenue | 11.9% | — | 9.1% | 66.5% | 120.9% | 125.8% | 170.0% | 53.7% | 70.0% | 36.7% |
| R&D / revenue | 78.0% | — | 106.0% | 683.3% | 1,147.6% | 1,046.5% | 1,196.8% | 600.5% | 476.4% | 312.0% |
| SG&A / revenue | 68.2% | — | 60.9% | 366.0% | 734.2% | 613.8% | 733.6% | 362.7% | 331.4% | 189.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 99.8 | — | 29.3 | 257.4 | 535.7 | 402.8 | 161.8 | 96.6 | 41.6 | 24.0 |
| Days of inventory on hand | — | — | — | -11.5 | — | — | — | — | -5,241.1 | -1,597.8 |
| Days payables outstanding | — | 283.8 | — | 1,666.6 | — | — | — | — | 5,026.2 | 3,329.2 |
| Cash conversion cycle (days) | — | — | — | -1,420.7 | — | — | — | — | -10,225.7 | -4,903.0 |
| Receivables turnover | 3.66 | 0.00 | 12.47 | 1.42 | 0.68 | 0.91 | 2.26 | 3.78 | 8.77 | 15.22 |
| Payables turnover | 0.00 | 1.29 | 0.00 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.11 |
| Inventory turnover | — | — | 0.00 | — | — | — | 0.00 | — | — | — |
| Asset turnover | 0.44 | 0.00 | 0.47 | 0.06 | 0.02 | 0.02 | 0.05 | 0.07 | 0.08 | 0.19 |
| Average receivables | €8.1M | €5.8M | €2.9M | €3.4M | €3.9M | €2.6M | €1.1M | €920,500 | €424,604 | €356,292 |
| Average payables | €5.5M | €5.6M | €5.3M | €4.5M | €5.3M | €5.9M | €5.3M | €4.8M | €4.8M | €4.0M |
| Average inventory | — | — | €1.6M | −€31,000 | −€21.7M | −€18.8M | €1.9M | −€1.9M | −€5.0M | −€1.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.2% | 0.2% | 0.0% |
Computed from NBTX's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
NBTX valuation and financial ratios
It ended the year with €95.3 million of debt and €52.8 million in cash and short-term investments, net debt of €42.6 million.
See the NBTX income statement, the NBTX chart for price history, or the NBTX stock overview for the latest quote and news.
NBTX key metrics FAQ
How much debt does Nanobiotix have?
Nanobiotix had total debt of €95.3 million at the end of fiscal 2025.
Does Nanobiotix pay a dividend?
Nanobiotix did not pay a dividend in fiscal 2025.
What is Nanobiotix's current ratio?
Nanobiotix's current ratio was 1.09 at the end of fiscal 2025: current assets were 1.09 times current liabilities.